Sapient provides multiomic biomarker discovery services based on high throughput mass spectrometry, bioinformatics, and access to a longitudinal human biology dataset. Sapient’s insights into dynamic biomarkers enable biopharma to make better decisions when prioritizing targets, patient populations, and drugs during discovery, development, clinical trials, or even following failed trials.
This multi-omics study, led by UPitt researchers, establishes causative linkages between key metabolites & PAH.
See how the partnership complements Sapient’s mass spectrometry-based proteomics & multi-omics services.
Dr. Jonathan Usuka appointed Chief Executive Officer as Founder Dr. Mohit Jain transitions to Chief Scientific Officer.
See how how the collaboration will enable accelerated delivery of multidimensional insights to inform drug development.
The paper details an innovative approach for assaying metabolic activities in intact human liver tissue.
See how these capabilities enhance the speed, quality & extent of metabolite identification for accelerated insights.
© Care Equity Capital Management L.P. New York, New York
